News

Foreign Policy Journal

The Foreign Policy Journal headline claims Lilly's Retatrutide delivered twice the weight loss of Ozempic, increasing competitive pressure on Novo Nordisk. The excerpt only repeats the headline and is too thin to substantively summarize or assess the comparison.

Google News

The provided text is too thin to summarize substantively: it contains only a headline and a repeated excerpt. The headline frames Novo Nordisk’s outlook around CagriSema data and competition from Lilly, but provides no results or supporting details.